Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10610)
All Articles published online
|
Publishing Process of This Article
|
Aug 28, 2020 (publication date) through Aug 31, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856 [PMID: 32921961 DOI: 10.3748/wjg.v26.i32.4846] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v26/i32/4846.htm |
| Number | Citing Articles |
| 1 |
Kaihao Lin, Lifang Huang, Yadong Wang, Kangkang Li, Yuanning Ye, Siqi Yang, Aimin Li. Efficacy of genotypic susceptibility‐guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta‐analysis. Helicobacter 2023; 28(6) doi: 10.1111/hel.13015
|
| 2 |
Si‐Yu Li, Jiang Li, Xin‐Hong Dong, Gui‐Gen Teng, Wei Zhang, Hong Cheng, Wen Gao, Yun Dai, Xiao‐He Zhang, Wei‐Hong Wang. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter 2021; 26(4) doi: 10.1111/hel.12804
|
| 3 |
Yoshio Yamaoka. Revolution of Helicobacter pylori treatment. Journal of Gastroenterology and Hepatology 2024; 39(6): 1016 doi: 10.1111/jgh.16526
|
| 4 |
Mahmood Alawainati, Murtadha M Ali, Mohamed AlShaalan, Husain I Hasan, Qasim M Jasim, Safiya Almusawi. Helicobacter pylori in Bahrain: A Comprehensive Study of Patient Characteristics, Treatment Approaches, and Cure Rates. Cureus 2025; doi: 10.7759/cureus.79341
|
| 5 |
Zhiqiang Song, Weihong Wang, Peng Li, Xiuli Zuo, Yin Zhu, Ye Chen, Xiaolan Zhang, Bin Lyu, Rong Lin, Yiqi Du, Cheng Lan, Hao Wu, Weixing Chen, Yanqing Ye, Huizhen Fan, Aijun Liao, Honghui Chen, Chengxia Liu, Zhenyu Zhang, Wen Wang, Zhimin Suo, Xiaoan Li, Qin Du, Xing Li, Feng Pan, Jianhua Tang, Min Xu, Xiongxiang Liu, Pengyuan Zheng, Huixin Chen, Ling Du, Jiayin Lu, Chun Feng, Wensheng Pan, Hong Wang, Zhirong Zeng, Jinhai Wang, Shengxiang Lyu, Dunju Liu, Shiming Yang, Liangping Li, Liya Zhou. Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trial. Chinese Medical Journal 2025; doi: 10.1097/CM9.0000000000003780
|
| 6 |
Natsuda Aumpan, Pornpen Gamnarai, Arti Wongcha-Um, Muhammad Miftahussurur, Yoshio Yamaoka, Ratha-korn Vilaichone. The use of real-world evidence to generate cost analysis of antibiotic susceptibility testing (AST) in patients with Helicobacter pylori treatment failure in Thailand: A large population-based study. Heliyon 2024; 10(21): e39189 doi: 10.1016/j.heliyon.2024.e39189
|
| 7 |
Marco Romano, Antonietta Gerarda Gravina, Leonardo Henry Eusebi, Raffaele Pellegrino, Giovanna Palladino, Leonardo Frazzoni, Elton Dajti, Antonio Gasbarrini, Francesco Di Mario, Rocco Maurizio Zagari, Antonio Benedetti, Bruno Annibale, Patrizia Burra, Marcello Fabio Maida, Francesco Luzza, Luigi Ricciardiello, Maurizio Vecchi, Luca Frulloni, Alessandro Repici, Edoardo Vincenzo Savarino, Luigi Pasquale, Antonio Pisani, Antonietta Lamazza, Gianpaolo Cengia, Enrico Ciliberto, Rita Luisa Conigliaro, Paola Da Massa Carrara, Bastianello Germanà. Management of Helicobacter pylori infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED). Digestive and Liver Disease 2022; 54(9): 1153 doi: 10.1016/j.dld.2022.06.019
|
| 8 |
Zinan Zhang, Fen Liu, Feiyan Ai, Xiong Chen, Rui Liu, Chao Zhang, Ning Fang, Tian Fu, Xiaoyan Wang, Anliu Tang. The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1143969
|
| 9 |
Tian-Lian Yan, Jing-Hua Wang, Xin-Jue He, Ya-Bi Zhu, Lin-Jie Lu, Yan-Jiao Wang, Zi-Wei Wang, Jian-Guo Gao, Cheng-Fu Xu, Han Ma, Shuang-Mei Luan, Lan Li, Yi Chen. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial. American Journal of Gastroenterology 2024; 119(4): 655 doi: 10.14309/ajg.0000000000002592
|
| 10 |
Hong-Lu Yu, Dong-Shuai Su, Shao-Ze Ma, Xing-Shun Qi. Approaches for detection of antibiotic resistance of Helicobacter pylori: Recent research advances. World Chinese Journal of Digestology 2023; 31(14): 571 doi: 10.11569/wcjd.v31.i14.571
|
| 11 |
XinBo Xu, Cong He, Yin Zhu. Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.998240
|
| 12 |
Xiaoye Shi, Chunmei Wang, Fanjun Meng, Shaoze Ma, Guangqin Xu, Tingwei Liu, Xiaozhong Guo, Hongyu Li, Xingshun Qi. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgraduate Medicine 2022; 134(7): 668 doi: 10.1080/00325481.2022.2105094
|
| 13 |
Sun Jae Moon, Ah Young Lee, Jinseub Hwang, Jun‐young Seo. Helicobacter pylori Eradication in Older Individuals: A Systematic Review and Meta‐Analysis. Helicobacter 2025; 30(4) doi: 10.1111/hel.70059
|
| 14 |
Tian‐Lian Yan, Jing‐Hua Wang, Ren‐Ke Zhu, Hao‐Liang Zhai, Zhen‐Zhen Wang, Xin‐Li Mao, Xian Shen, Ping Xu, Dan Ma, Xin‐Jue He, Jie‐Wei Wang, Jian‐Guo Gao, Ling‐Ling Jiang, Kefang Sun, Ye Chen, Jian‐Zhong Sang, Xiao‐Qin Liu, Jiao‐E Chen, Lan Li. Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial. Helicobacter 2025; 30(4) doi: 10.1111/hel.70056
|
| 15 |
Prateek Sharma, Shravani M. Phatak, Prisha Warikoo, Akshita Mathur, Shweta Mahant, Kunal Das, Rajashree Das. Crosstalk between Helicobacter pylori and gastrointestinal microbiota in various gastroduodenal diseases—A systematic review. 3 Biotech 2023; 13(9) doi: 10.1007/s13205-023-03734-5
|
| 16 |
András Gelley, Noémi Kéri, Péter Birinyi, Kinga Komka, Vajk Hardy, László Döngölő, Dóra Szeli, Ibolya Czegle. Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and/or Bismuth) to Helicobacter pylori Eradication Protocols in a Clarithromycin Resistant and Tetracycline/Bismuth Naive Area: A Real-World Data Retrospective Analysis of 402 Cases (2016–24) in a Single Gastroenterology Unit. Antibiotics 2025; 14(9): 870 doi: 10.3390/antibiotics14090870
|
| 17 |
Hazem Abosheaishaa, Hesham Elsayed, Omar Abdelhalim, Islam Mohsen El Haddad, Mohamed K. Harfoush, Abdallfatah Abdallfatah, Arshia Sethi, Mohammed Abusuliman, Rahul Karna, Mohammad Bilal.
Vonoprazan and amoxicillin dual therapy versus bismuth-based therapy for
Helicobacter pylori
eradication: a systematic review and meta-analysis of randomized controlled trials
. Baylor University Medical Center Proceedings 2025; 38(5): 716 doi: 10.1080/08998280.2025.2491964
|
| 18 |
Bo Shen Lin, Yue Yue Li, Chen Qiao, Jing Liu, Juan Wang, Meng Wan, Min Juan Lin, Wen Lin Zhang, Yu Ming Ding, Qing Zhou Kong, Miao Duan, Xiu Li Zuo, Yan Qing Li. Implementation of WeChat‐based patient–doctor interaction in the management of Helicobacter pylori infection: A propensity score matching analysis. Journal of Digestive Diseases 2022; 23(5-6): 280 doi: 10.1111/1751-2980.13114
|
| 19 |
Pezhman Alavinejad, Morteza Nayebi, Abazar Parsi, Eman Abdelsameea, Mohammed Hussien Ahmed, Ahmad Hormati, Dao Viet Hang, Mehdi Pezeshgi Modarres, Bahman Cheraghian, Siamak Baghaee, Tahmine Farbod Ara, Quang Trung Tran, Nitin Shanker Behl, Seyed Jalal Hashemi, Mohammed Alboraie, Saif Salman, Le Nha, Árpád V. Patai, Eskandar Hajiani, Ali Akbar Abravesh. Levofloxacin+Tetracycline Quadruple Regimen for Eradication of Helicobacter pylori: A Multicenter Multinational Randomized Controlled Trial. Middle East Journal of Digestive Diseases 2023; 15(1): 12 doi: 10.34172/mejdd.2023.314
|
| 20 |
Yongfu Shao, Yifan Lin, Ziyi Fang, Jianing Yan, Tuo Zheng, Guoliang Ye. Analysis of Helicobacter pylori resistance in patients with different gastric diseases. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-55589-2
|
| 21 |
明远 辛. Research Status of Helicobacter pylori Infection in High Altitude Areas. Advances in Clinical Medicine 2022; 12(05): 4571 doi: 10.12677/ACM.2022.125660
|
| 22 |
Oscar Laudanno, Gabriel Ahumarán, Marcelo Thomé, Pablo Gollo, Patricia Gonzalez, Marina Khoury. Relationship between obesity severity and Helicobacter pylori eradication in patients undergoing bariatric and metabolic surgery: A post hoc analysis. Obesity Surgery 2024; 34(10): 3790 doi: 10.1007/s11695-024-07505-w
|
| 23 |
Sintayehu Fekadu, Seyife Kibru, Sisay Tesfaye, Tariku Egeno, Alemu Tamiso, Hizkel Engiso, Serawit Deyno. Prevalence of Helicobacter pylori infection and effectiveness of first-line triple eradication therapy among dyspeptic patients at hospitals in Hawassa City, Ethiopia: a cross-sectional follow-up study. Gut Pathogens 2024; 16(1) doi: 10.1186/s13099-024-00618-8
|
| 24 |
Mahboobe Ebrahimi, Sepehr Tirgar Fakheri, Faezeh Aeeni, Tarang Taghvaei, Mehdi Saberi Firoozi, Hafez Fakheri. An Update on Eradication of Helicobacter Pylori in Iran: A Review. Middle East Journal of Digestive Diseases 2024; 16(3): 147 doi: 10.34172/mejdd.2024.389
|
| 25 |
Rinki Sisodia, Pooja Anjali Mazumdar, Chaithanya Madhurantakam. In silico identification and analysis of potential inhibitors for acid phosphatase, HppA from Helicobacter pylori. Journal of Molecular Recognition 2023; 36(9) doi: 10.1002/jmr.3049
|
| 26 |
Xiaoduan Zhuang, Huiyue Jiang, Dandan Jin, Meiling Sun, Zhenwu Wang, Xinying Wang. The efficacy and safety of vonoprazan in quadruple therapy for Helicobacter pylori eradication: a comparative study. Gastroenterology Report 2023; 12 doi: 10.1093/gastro/goae036
|
| 27 |
Muhammad Umair Mazhar, Hafiz Muhammad Ahmad Anees, Samana Mukhtar, Humna Irshad, Ayman Irshad, Abdul Moizz, Abdul Eizad Asif, Hassan Durrani, Haiqa Asif, Hannan Hashmat, Muhammad Khizer Azeem. Efficacy of Concomitant Therapy Versus Triple Therapy in Eradicating Helicobacter pylori Infection: A Retrospective Study. Cureus 2025; doi: 10.7759/cureus.87322
|
| 28 |
Jianping Cheng, Chanjuan Fan, Zhen Li, Zhaojing Dong, Xiaolin Zhao, Yong Cai, Haiou Ding, Yan Dou, Xiaomei Zhang. Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study. Clinical and Experimental Gastroenterology 2024; : 191 doi: 10.2147/CEG.S466975
|
| 29 |
Meng Li, Xiaolei Wang, Xinhong Dong, Guigen Teng, Yun Dai, Weihong Wang.
Vonoprazan–minocycline dual therapy as a first-line treatment of
Helicobacter pylori
infection compared with empirical bismuth-containing quadruple therapy
. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251366156
|
| 30 |
Dan Ma, Yunhui Fang, ZiWei Wang, Mosang Yu, Xin Xin Zhou. Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Eradication Therapy in the Southeast Region of China: A Retrospective Study. Infection and Drug Resistance 2024; : 5079 doi: 10.2147/IDR.S487503
|
| 31 |
Zixing Wang, Wei Han, Fang Xue, Yujie Zhao, Peng Wu, Yali Chen, Cuihong Yang, Wentao Gu, Jingmei Jiang. Nationwide gastric cancer prevention in China, 2021–2035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut 2022; 71(12): 2391 doi: 10.1136/gutjnl-2021-325948
|
| 32 |
Pavle Vrebalov Cindro, Josipa Bukic, Shelly Pranić, Dario Leskur, Doris Rušić, Ana Šešelja Perišin, Joško Božić, Jonatan Vuković, Darko Modun. Did an introduction of CONSORT for abstracts guidelines improve reporting quality of randomised controlled trials’ abstracts onHelicobacter pyloriinfection? Observational study. BMJ Open 2022; 12(3): e054978 doi: 10.1136/bmjopen-2021-054978
|
| 33 |
Jin-Yan Zhang, Jin-Hai Chen, Yu-Lin Huang, Ji Li, Dong Xu, Zhong Xu, Xiao-Yi Lei.
Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for
Helicobacter pylori
treatment: a randomized clinical trial
. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251354868
|
| 34 |
Ahmed M. Elgamal, Eman AboBakr Ali, Gamal R. Saad, Ismail A. Abdelhamid, Maher Z. Elsabee, Amira A. Hamed. Biologically active ionic chitosan Schiff base nanocomposites: Synthesis, characterization and antimicrobial activity against Helicobacter pylori. International Journal of Biological Macromolecules 2024; 282: 137321 doi: 10.1016/j.ijbiomac.2024.137321
|
| 35 |
A Reum Choe, Ki-Nam Shim, Yehyun Park, Eun-Mi Song, Chung Hyun Tae, Sung-Ae Jung. Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients with Helicobacter pylori Infection. Journal of Clinical Medicine 2021; 10(12): 2619 doi: 10.3390/jcm10122619
|